← Eichor
Study identifier: NCT06229626 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of an Intensive Training Program for Patients with Hereditary Spastic Paraparesis SPG4/Spast

Condition: Hereditary Spastic Paraparesis  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseNA
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Hereditary spastic paraparesis is a group of inherited neurological diseases. Only symptomatic treatments exist for the moment. The Modifspa study (cf citation) carried out by the team showed that patients perceived a feeling of effectiveness of physiotherapy on lower limb spasticity. The aim of the Walk-up study is to objectivize this feeling of efficacy on gait disorders in these patients. This is an interventional study using physical training. The study is prospective, open, randomized in 2 parallel groups, one of which is a control group. Analyses will be comparative between the 2 groups during the course of the study.

This description comes directly from the study's public registry record.

Talk to the study team

Pauline Lallemant, MD  ·  1. 57.27.46.69  ·  pauline.lallemant@icm-institute.org

Rania Hilab, CRA  ·  1. 57.27.46.91  ·  rania.hilab@icm-institute.org

Always discuss trial participation with your own doctor first.

Locations (1)

ICM, Hôpital Pitié-SalpêtrièreParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06229626